High-dose chemotherapy with carmustine, etoposide, cytarabine and melphalan followed by autologous stem cell transplant is an effective treatment for elderly patients with poor-prognosis lymphoma

References

• Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014. CA Cancer J Clin 2014;64:9–29.
   PubMed Web of Science ®Google Scholar
• A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993;329:987–994.
   PubMed Web of Science ®Google Scholar
• Thieblemont C, Coiffier B. Lymphoma in older patients. J Clin Oncol 2007;25:1916–1923.
   PubMed Web of Science ®Google Scholar
• Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995;333:1540–1545.
   PubMed Web of Science ®Google Scholar
• Haioun C, Lepage E, Gisselbrecht C, et al. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol—a groupe d’Etude des lymphomes de l’Adulte study. J Clin Oncol 2000;18:3025–3030.
   PubMed Web of Science ®Google Scholar
• Milpied N, Deconinck E, Gaillard F, et al. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med 2004;350:1287–1295.
   PubMed Web of Science ®Google Scholar
• Stiff PJ, Unger JM, Cook JR, Constine LS, Couban S, Stewart DA, et al. Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma. N Engl J Med 2013;369:1681–90.
   PubMed Web of Science ®Google Scholar
• Khouri IF, Romaguera J, Kantarjian H, et al. Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol 1998;16:3803–3809.
   PubMed Web of Science ®Google Scholar
• Van't Veer MB, de Jong D, MacKenzie M, et al. High-dose Ara-C and beam with autograft rescue in R-CHOP responsive mantle cell lymphoma patients. Br J Haematol 2009;144:524–530.
   PubMed Web of Science ®Google Scholar
• Geisler CH, Kolstad A, Laurell A, et al. Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur. Br J Haematol 2012;158:355–362.
   PubMed Web of Science ®Google Scholar
• Dreyling M, Lenz G, Hoster E, et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood 2005;105: 2677–2684.
   PubMed Web of Science ®Google Scholar
• Abrey LE, Moskowitz CH, Mason WP, et al. Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis. J Clin Oncol 2003;21:4151–4156.
   PubMed Web of Science ®Google Scholar
• Colombat P, Lemevel A, Bertrand P, et al. High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group. Bone Marrow Transplant 2006;38:417–420.
   PubMed Web of Science ®Google Scholar
• D’Amore F, Relander T, Lauritzsen GF, et al. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol 2012;30:3093–3099.
   PubMed Web of Science ®Google Scholar
• Mounier N, Gisselbrecht C. Conditioning regimens before transplantation in patients with aggressive non-Hodgkin's lymphoma. Ann Oncol 1998;9:S15–S21.
   PubMed Web of Science ®Google Scholar
• Jantunen E, Kuittinen T, Penttilä K, et al. High-dose melphalan (200 mg/m2) supported by autologous stem cell transplantation is safe and effective in elderly (> or = 65 years) myeloma patients: comparison with younger patients treated on the same protocol. Bone Marrow Transplant 2006;37:917–922.
   PubMed Web of Science ®Google Scholar
• Kumar SK, Dingli D, Lacy MQ, et al. Autologous stem cell transplantation in patients of 70 years and older with multiple myeloma: results from a matched pair analysis. Am J Hematol 2008;83:614–617.
   PubMed Web of Science ®Google Scholar
• Stamatoullas A, Fruchart C, Khalfallah S, et al. Peripheral blood stem cell transplantation for relapsed or refractory aggressive lymphoma in patients over 60 years of age. Bone Marrow Transplant 1997;19:31–35.
   PubMed Web of Science ®Google Scholar
• Moreau P, Milpied N, Voillat L, et al. Peripheral blood stem cell transplantation as front-line therapy in patients aged 61 to 65 years: a pilot study. Bone Marrow Transplant 1998;21:1193–1196.
   PubMed Web of Science ®Google Scholar
• Jantunen E, Mahlamäki E, Nousiainen T. Feasibility and toxicity of high-dose chemotherapy supported by peripheral blood stem cell transplantation in elderly patients (>/ = 60 years) with non-Hodgkin's lymphoma: comparison with patients < 60 years treated within the same protocol. Bone Marrow Transplant 2000;26:737–741.
   PubMed Web of Science ®Google Scholar
• Gopal AK, Gooley TA, Golden JB, et al. Efficacy of high-dose therapy and autologous hematopoietic stem cell transplantation for non-Hodgkin's lymphoma in adults 60 years of age and older. Bone Marrow Transplant 2001;27:593–599.
   PubMed Web of Science ®Google Scholar
• Bitran JD, Klein L, Link D, et al. High-dose myeloablative therapy and autologous peripheral blood progenitor cell transplantation for elderly patients (greater than 65 years of age) with relapsed large cell lymphoma. Biol Blood Marrow Transplant 2003;9:383–388.
   PubMed Web of Science ®Google Scholar
• Magagnoli M, Castagna L, Balzarotti M, et al. Feasibility and toxicity of high-dose therapy (HDT) supported by peripheral blood stem cells in elderly patients with multiple myeloma and non-Hodgkin's lymphoma: survey from a single institution. Am J Hematol 2003;73:267–272.
   PubMed Web of Science ®Google Scholar
• Buadi FK, Micallef IN, Ansell SM, et al. Autologous hematopoietic stem cell transplantation for older patients with relapsed non-Hodgkin's lymphoma. Bone Marrow Transplant 2006;37:1017–1022.
   PubMed Web of Science ®Google Scholar
• Jantunen E, Itälä M, Juvonen E, et al. Autologous stem cell transplantation in elderly (> 60 years) patients with non-Hodgkin's lymphoma: a nation-wide analysis. Bone Marrow Transplant 2006;37:367–372.
   PubMed Web of Science ®Google Scholar
• Gopal AK, Rajendran JG, Gooley TA, et al. High-dose [131I]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults > or = 60 years old with relapsed or refractory B-cell lymphoma. J Clin Oncol 2007;25: 1396–1402.
   PubMed Web of Science ®Google Scholar
• Hosing C, Saliba RM, Okoroji G-J, et al. High-dose chemotherapy and autologous hematopoietic progenitor cell transplantation for non-Hodgkin's lymphoma in patients > 65 years of age. Ann Oncol 2008;19:1166–1171.
   PubMed Web of Science ®Google Scholar
• Jantunen E, Canals C, Rambaldi A, et al. Autologous stem cell transplantation in elderly patients (> or = 60 years) with diffuse large B-cell lymphoma: an analysis based on data in the European Blood and Marrow Transplantation registry. Haematologica 2008; 93:1837–1842.
   PubMed Web of Science ®Google Scholar
• Yusuf RZ, Dey B, Yeap BY, et al. Autologous SCT with a dose-reduced BU and CY regimen in older patients with non-Hodgkin's lymphoma. Bone Marrow Transplant 2009;43:37–42.
   PubMed Web of Science ®Google Scholar
• Puig N, Pintilie M, Seshadri T, et al. High-dose chemotherapy and auto-SCT in elderly patients with Hodgkin's lymphoma. Bone Marrow Transplant 2011;46:1339–1344.
   PubMed Web of Science ®Google Scholar
• Jantunen E, Canals C, Attal M, et al. Autologous stem-cell transplantation in patients with mantle cell lymphoma beyond 65 years of age: a study from the European Group for Blood and Marrow Transplantation (EBMT). Ann Oncol 2012;23:166–171.
   PubMed Web of Science ®Google Scholar
• Chihara D, Izutsu K, Kondo E, et al. High-dose chemotherapy with autologous stem cell transplantation for elderly patients with relapsed/refractory diffuse large B cell lymphoma: a nationwide retrospective study. Biol Blood Marrow Transplant 2014;20:684–689.
   PubMed Web of Science ®Google Scholar
• Zallio F, Cuttica A, Caracciolo D, et al. Feasibility of peripheral blood progenitor cell mobilization and harvest to support chemotherapy intensification in elderly patients with poor prognosis: non-Hodgkin's lymphoma. Ann Hematol 2002;81:448–453.
   PubMed Web of Science ®Google Scholar
• Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005;106:2912–2919.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244.
   PubMed Web of Science ®Google Scholar
• Shimoni A, Avivi I, Rowe JM, et al. A randomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma. Cancer 2012;118:4706–4714.
   PubMed Web of Science ®Google Scholar
• Gastaud L. Prévention des infections systémiques à streptocoques viridans par bains de bouche à la vancomycine en soins intensifs d'hématologie. Poster presented at Annual Meeting of the French Society of Bonne Marrow Transplantation and Cellular Therapy, 27–28 October 2011, Paris, France. Available from: sfgm-tc.com/abstractssfgmtc2011poster21.html
   Google Scholar
• Thieblemont C, Dumontet C, Saad H, et al. Amifostine reduces mucosal damage after high-dose melphalan conditioning and autologous peripheral blood progenitor cell transplantation for patients with multiple myeloma. Bone Marrow Transplant 2002;30:769–775.
   PubMed Web of Science ®Google Scholar
• Italiano A, Chamorey E, Foa C, et al. Amifostine can reduce oral mucositis after high-dose melphalan conditioning in patients with multiple myeloma: a retrospective study. Blood 2004;104(Suppl. 1): Abstract 5022.
   PubMed Web of Science ®Google Scholar
• A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997;89:3909–3918.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Schubert J, Ziepert M, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20 + B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 2008;9:105–116.
   PubMed Web of Science ®Google Scholar
• Advani RH, Chen H, Habermann TM, et al. Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B-cell lymphoma treated with R-CHOP in the US Intergroup Study (ECOG 4494, CALGB 9793): consideration of age greater than 70 years in an elderly prognostic index (E-IPI). Br J Haematol 2010;151:143–151.
   PubMed Web of Science ®Google Scholar
• Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol 2005;23:4117–4126.
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373–383.
   PubMedGoogle Scholar
• Jones JA, Qazilbash MH, Shih Y-CT, et al. In-hospital complications of autologous hematopoietic stem cell transplantation for lymphoid malignancies. Cancer 2008;112:1096–1105.
   PubMed Web of Science ®Google Scholar
• Plattel WJ, Kluin-Nelemans HC, de Bock GH, et al. Prognostic value of comorbidity for auto-SCT eligibility and outcome in relapsed or refractory aggressive non-Hodgkin's lymphoma. Bone Marrow Transplant 2011;46:827–834.
   PubMed Web of Science ®Google Scholar
• Nabhan C, Smith SM, Helenowski I, et al. Analysis of very elderly (≥ 80 years) non-hodgkin lymphoma: impact of functional status and co-morbidities on outcome. Br J Haematol 2012;156: 196–204.
   PubMed Web of Science ®Google Scholar
• Winkelmann N, Petersen I, Kiehntopf M, et al. Results of comprehensive geriatric assessment effect survival in patients with malignant lymphoma. J Cancer Res Clin Oncol 2011;137: 733–738.
   PubMed Web of Science ®Google Scholar
• Peyrade F, Gastaud L, Ré D, et al. Treatment decisions for elderly patients with haematological malignancies: a dilemma. Lancet Oncol 2012;13:e344–e352.
   PubMed Web of Science ®Google Scholar
• Klaus J, Herrmann D, Breitkreutz I, et al. Effect of CD34 + cell dose on hematopoietic reconstitution and outcome in 508 patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation. Eur J Haematol 2007;78:21–28.
   PubMed Web of Science ®Google Scholar
• Morris CL, Siegel E, Barlogie B, et al. Mobilization of CD34 + cells in elderly patients (≥ 70 years) with multiple myeloma: influence of age, prior therapy, platelet count and mobilization regimen. Br J Haematol 2003;120:413–423.
   PubMed Web of Science ®Google Scholar
• Blijlevens N, Schwenkglenks M, Bacon P, et al. Prospective oral mucositis audit: oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy—European Blood and Marrow Transplantation Mucositis Advisory Group. J Clin Oncol 2008;26:1519–1525.
   PubMed Web of Science ®Google Scholar
• Spencer A, Horvath N, Gibson J, et al. Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation. Bone Marrow Transplant 2005;35:971–977.
   PubMed Web of Science ®Google Scholar
• Mounier N, El Gnaoui T, Tilly H, et al. Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trial. Haematologica 2013;98:1726–1731.
   PubMed Web of Science ®Google Scholar